Approval · Notice of Compliance 26729 · 2021
PRO-GABAPENTIN: Notice of Compliance 26729
Issued September 24, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26729
- Date
- September 24, 2021
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Administrative: Labelling Update (to Match Licensor) Updates to labels to align with Plain Language Labelling Regulations
- Canadian reference product
- NEURONTIN (Parke-Davis Division, Warner-Lambert Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRO-GABAPENTIN | Not yet assigned | — |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP